CRISPR Therapeutics AG
- Open
- 54.56
- Day high
- 57.25
- Day low
- 54.56
- Prev close
- 54.54
- Volume
- 496K
- Mkt cap
- $5.4B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.0
- P/S
- 1314.3
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$211K over the last 3 months (0 open-market buys, 1 sale)
- 🏛Institutions accumulating (13F)
CRISPR Therapeutics AG (CRSP) is a Healthcare company listed on NASDAQ. The stock is up 12% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 1 sale (SEC Form 4).
CRISPR Therapeutics AG (CRSP) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
CRSP earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 4, 2026 | $-1.20 | $-1.28 | -6.6% | $1M | -76.0% |
| Feb 12, 2026 | $-1.15 | $-1.37 | -19.1% | $864000 | -81.7% |
| Feb 21, 2024 | $-0.07 | $1.10 | +1671.4% | $200M | +611.5% |
| Feb 21, 2023 | $-2.32 | $-1.41 | +39.2% | $6000 | -73.9% |
| Nov 1, 2022 | $-2.30 | $-2.24 | +2.6% | $94000 | -94.9% |
| Feb 15, 2022 | $-1.74 | $-1.84 | -5.7% | $12M | +465.0% |
| Nov 3, 2021 | $-1.69 | $-1.67 | +1.2% | $329000 | -60.5% |
| Jul 29, 2021 | $3.52 | $9.44 | +168.2% | $900M | +6.4% |
| Feb 16, 2021 | $-1.23 | $-1.50 | -22.0% | $194000 | -92.2% |
| Oct 28, 2020 | $-1.17 | $-1.32 | -12.8% | $148000 | +11.9% |
| Jul 27, 2020 | $-0.92 | $-1.30 | -41.3% | $44000 | +36.8% |
| Apr 28, 2020 | $-1.09 | $-1.15 | -5.5% | $157000 | +9.5% |
CRSP insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 9, 2026 | High Katherine Adirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Greene Johndirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Rommel Christiandirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Fardis Mariadirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Behbahani Alidirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Morrison Briggsdirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | George Simeondirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Mahatme Sandeshdirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Treco Douglas Adirector | Grant | 13,000 | $51.84 |
| Jun 9, 2026 | Fleming Harold Edwarddirector | Grant | 13,000 | $51.84 |
| Jun 2, 2026 | Patel Naimishofficer: Chief Medical Officer | Grant | 22,000 | — |
| Jun 2, 2026 | KASINGER JAMES R.officer: General Counsel and Secretary | Grant | 17,000 | — |
| Jun 2, 2026 | Prasad Rajuofficer: Chief Financial Officer | Grant | 19,500 | — |
| Jun 1, 2026 | Patel Naimishofficer: Chief Medical Officer | Option | 10,000 | — |
| Jun 1, 2026 | Patel Naimishofficer: Chief Medical Officer | Sell | 3,786 | $55.62 |
Source: CRSP SEC Form 4 filings, latest Jun 9, 2026. For informational purposes only — not investment advice.
See the full CRSP insider & 13F page →CRISPR Therapeutics AG company profile
Overview
CRISPR Therapeutics AG (NASDAQ:CRSP) is a Swiss-based gene editing company founded in 2013 that develops gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform technology. The company went public in October 2016 and has emerged as one of the leading players in the rapidly evolving field of gene editing therapeutics. CRISPR Therapeutics focuses on creating treatments for conditions ranging from blood disorders to cancer and diabetes, with its lead therapy CTX001 representing one of the first CRISPR-based treatments to advance through clinical trials toward potential regulatory approval.
Business
CRISPR Therapeutics operates in the biotechnology sector, specifically in the gene editing space, where it develops therapeutic treatments by precisely modifying patients' genetic material to treat or cure diseases. The company's core technology platform is based on CRISPR/Cas9, which stands for Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9. This technology functions like molecular scissors that can cut DNA at specific locations, allowing scientists to remove, add, or alter particular DNA sequences with unprecedented precision. The company's therapeutic pipeline spans multiple disease areas. CTX001 is the lead product candidate, an ex vivo gene-edited therapy designed to treat patients with transfusion-dependent beta-thalassemia and severe sickle cell disease. This treatment works by editing a patient's own hematopoietic stem cells (blood-forming cells) outside the body to produce high levels of fetal hemoglobin, which can compensate for defective adult hemoglobin in these inherited blood disorders. In oncology, CRISPR Therapeutics develops several allogeneic CAR-T therapies, which are cancer treatments using donor-derived immune cells that have been genetically modified to better attack cancer cells. These include CTX110 for blood cancers expressing CD19, CTX120 for multiple myeloma targeting BCMA, and CTX130 for various solid tumors and blood cancers targeting CD70. The advantage of allogeneic therapies is that they can be manufactured at scale from healthy donor cells, rather than requiring individual patient cell collection and modification. The company also pursues regenerative medicine through VCTX210, a gene-edited stem cell-derived therapy for type 1 diabetes, and various in vivo gene editing programs that target diseases in the liver, lung, muscle, and central nervous system by delivering gene editing tools directly into patients' bodies. Revenue generation is currently limited and primarily comes from strategic partnerships and collaboration agreements, with 2024 full-year revenue of $35 million compared to $371 million in 2023, indicating the lumpy nature of partnership milestone payments in the biotech industry.
Revenue model
CRISPR Therapeutics operates under a typical biotech business model where revenue generation occurs through multiple channels, though the company is still in the pre-commercialization phase for most of its pipeline. The primary revenue sources include strategic partnership agreements, milestone payments, research collaboration fees, and licensing arrangements with pharmaceutical companies like Vertex Pharmaceuticals, Bayer Healthcare, ViaCyte, Nkarta, and Capsida Biotherapeutics. The company's partnership with Vertex Pharmaceuticals for CTX001 represents a significant revenue opportunity, as Vertex handles much of the commercial development and the companies share costs and potential profits. When CTX001 and other therapies eventually reach market approval, CRISPR Therapeutics will generate revenue through product sales, royalties, and profit-sharing arrangements. Several factors significantly impact the company's financial performance and future profitability. Regulatory approval timelines represent the most critical factor, as delays in clinical trials or FDA/EMA approval processes directly affect when revenue generation can begin. Clinical trial success rates determine whether the substantial R&D investments will yield marketable products, with each failed program representing sunk costs. Manufacturing scalability and costs will heavily influence margins, particularly for complex cell therapies that require sophisticated production facilities and quality control measures. Competitive pressures from other gene editing companies, traditional pharmaceutical approaches, and emerging technologies could compress pricing power and market share. Intellectual property landscape affects both licensing costs and the ability to maintain competitive advantages. Healthcare reimbursement policies will determine market access and pricing for these expensive, cutting-edge therapies. Additionally, manufacturing capacity constraints and the specialized nature of gene editing therapies create both opportunities for premium pricing and risks of supply bottlenecks that could limit revenue growth even after successful product launches.
Competitive moat
CRISPR Therapeutics possesses several competitive advantages, though the durability of these moats faces significant challenges in the rapidly evolving gene editing landscape. The company's primary moat stems from its extensive intellectual property portfolio and early-mover advantage in CRISPR/Cas9 applications for therapeutic use. As one of the pioneering companies in the space, CRISPR Therapeutics has accumulated valuable clinical data, regulatory experience, and manufacturing know-how that creates barriers for later entrants. The company's strategic partnerships, particularly with Vertex Pharmaceuticals, provide significant competitive advantages through shared resources, reduced financial risk, and access to Vertex's commercial infrastructure and regulatory expertise. These partnerships also validate CRISPR's technology platform and provide credibility that can be difficult for smaller competitors to replicate. However, the company's moat faces substantial threats. The intellectual property landscape in gene editing remains highly contested, with ongoing patent disputes and the potential for competitors to develop alternative approaches that circumvent existing patents. Companies like Editas Medicine, Intellia Therapeutics, and Beam Therapeutics are pursuing similar or complementary gene editing technologies, while traditional pharmaceutical giants are either developing internal capabilities or acquiring gene editing companies. Technological disruption represents another significant risk, as newer gene editing technologies like base editing, prime editing, or entirely different approaches could potentially offer superior safety, efficacy, or cost profiles. The company's focus on ex vivo therapies, while currently advantageous, could become a limitation if in vivo delivery methods prove more commercially viable. The competitive moat is further challenged by the high capital requirements and regulatory expertise needed for gene editing therapies, which paradoxically both protect existing players and attract well-funded competitors. Large pharmaceutical companies with deeper pockets and broader pipelines may be able to sustain longer development timelines and absorb more failures than specialized biotech companies like CRISPR Therapeutics.
Risks & safety
CRISPR Therapeutics maintains a relatively strong financial position despite operating losses typical of pre-revenue biotech companies, though cash burn rates require careful monitoring. • Liquidity position: Strong current ratio of 22.1x with $298 million in cash and short-term investments as of Q4 2024, providing adequate runway for operations • Cash burn: Free cash flow negative $145 million for full year 2024, indicating approximately 2+ years of cash runway at current burn rates • Debt levels: Low debt-to-equity ratio of 0.12, minimal solvency risk with total liabilities of $310 million against $2.2 billion in total assets • Valuation metrics: Trading at 1.7x price-to-book ratio, which appears reasonable given the company's asset base and pipeline value • Operating losses: Net loss of $366 million in 2024, though this includes substantial R&D investments in pipeline development • Revenue volatility: Lumpy partnership revenue ($35M in 2024 vs $371M in 2023) creates forecasting challenges but reflects milestone-driven business model • Clinical risk: Pipeline success heavily dependent on regulatory approvals and clinical trial outcomes, with binary risk/reward profile typical of biotech investments
Recent development
Based on the financial data trends, CRISPR Therapeutics has been navigating the typical biotech development cycle with significant R&D investments and partnership-driven revenue fluctuations. The company's revenue dropped dramatically from $371 million in 2023 to $35 million in 2024, reflecting the milestone-based nature of biotech partnerships where large payments are received when specific development or regulatory milestones are achieved. The company has maintained substantial cash reserves while continuing to invest heavily in clinical development, with operating cash flow losses of $143 million in 2024 compared to $260 million in 2023, suggesting some improvement in cash management efficiency. The consistent current ratios above 15x indicate strong liquidity management and the ability to fund operations through multiple development cycles. Recent strategic developments appear focused on advancing the clinical pipeline, particularly the lead program CTX001 in partnership with Vertex Pharmaceuticals. The company's asset base has remained relatively stable around $2.2-2.3 billion, suggesting continued investment in manufacturing capabilities, clinical infrastructure, and intellectual property development. The partnership strategy continues to be central to CRISPR's development approach, providing both financial support and risk-sharing for expensive clinical programs. The company's ability to maintain strong balance sheet metrics while pursuing multiple therapeutic programs simultaneously indicates disciplined capital allocation and successful partnership structuring that reduces individual program risk exposure.
CRSP company profile · for informational purposes only — not investment advice.
Track CRSP with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free